Key Details
Annual Revenue
$19.64 MAnnual ROE
-352.22%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 17, 2023Recent annual earnings:
Mar 10, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
30 Aug '22 HC Wainwright & Co.
Neutral03 June '22 Cantor Fitzgerald
Overweight26 Apr '22 Canaccord Genuity
Buy28 Mar '22 HC Wainwright & Co.
Buy28 Mar '22 Aegis Capital
Buy29 Nov '21 HC Wainwright & Co.
Buy12 Jan '21 SVB Leerink
Outperform04 Jan '21 HC Wainwright & Co.
Buy09 Nov '20 JP Morgan
Underweight05 Oct '20 HC Wainwright & Co.
BuyScreeners with OBSV included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
ObsEva SA doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of ObsEva SA?
- What is the ticker symbol for ObsEva SA?
- Does ObsEva SA pay dividends?
- What sector is ObsEva SA in?
- What industry is ObsEva SA in?
- What country is ObsEva SA based in?
- When did ObsEva SA go public?
- Is ObsEva SA in the S&P 500?
- Is ObsEva SA in the NASDAQ 100?
- Is ObsEva SA in the Dow Jones?
- When was ObsEva SA's last earnings report?
- When does ObsEva SA report earnings?
- Should I buy ObsEva SA stock now?
What is the primary business of ObsEva SA?
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
What is the ticker symbol for ObsEva SA?
The ticker symbol for ObsEva SA is NASDAQ:OBSV
Does ObsEva SA pay dividends?
No, ObsEva SA does not pay dividends
What sector is ObsEva SA in?
ObsEva SA is in the Healthcare sector
What industry is ObsEva SA in?
ObsEva SA is in the Biotechnology industry
What country is ObsEva SA based in?
ObsEva SA is headquartered in Switzerland
When did ObsEva SA go public?
ObsEva SA's initial public offering (IPO) was on 13 July 2018
Is ObsEva SA in the S&P 500?
No, ObsEva SA is not included in the S&P 500 index
Is ObsEva SA in the NASDAQ 100?
No, ObsEva SA is not included in the NASDAQ 100 index
Is ObsEva SA in the Dow Jones?
No, ObsEva SA is not included in the Dow Jones index
When was ObsEva SA's last earnings report?
ObsEva SA's most recent earnings report was on 17 May 2023
When does ObsEva SA report earnings?
The date for ObsEva SA's next earnings report has not been announced yet
Should I buy ObsEva SA stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions